Gene switches have garnered significant attention from drug developers owing to their ability to control the activity of genetically modified cell products in vivo

The global gene switch market size is estimated to grow from USD 795 million in 2025 to USD 2,478 million by 2035, representing a CAGR of 12.03% during the forecast period till 2035.

Driven by numerous developmental breakthroughs and encouraging study results demonstrating the vast potential of adoptive cell therapies (ACT), including CAR-T cell therapies, TCR therapies, TILs and natural killer cell therapies, in the treatment of various complex disorders, this therapeutic modality has garnered considerable attention from the players engaged in the pharmaceutical industry. In fact, in the past few years, close to 30 cell and gene therapies have been approved by the US FDA.

Foreseeing the lucrative potential within this domain, a large number of players have made investments worth usd 3.5 billion to advance the initiatives of industry stakeholders

Over the years, monetary assistance from angel investors, venture capitalists and funding schemes of various public and private organizations, along with assistance from regulatory authorities, has allowed start-ups / small companies to further expand their R&D efforts related to gene switch domain. The technological advancements in this domain, coupled to the promising results reported, have garnered the attention of several investors. Given the innate advantages offered by gene switch platforms in gene therapies, this emerging market has done exceedingly well in terms of raising funds. The strong and steady performance, in terms of research-related advances and flow of finances, has been favorable to this market. It is worth highlighting that the investments from secondary offerings and venture series have helped several start-ups to become the current leaders in the domain.

There has been a steady increase in the funding activity; specifically, in 2021, industry players collectively raised close to USD 1.25 billion. Close to USD 910 million has been raised by stakeholders through secondary offering; further, over USD 800 million, so far, has been raised through venture series. More than 80% of the players that have raised significant capital are based in North America; majority of such players are mid-sized  and large players.

Scientific articles being published for gene switch, reflect the growing research efforts of various industry and academic stakeholders

Scientific articles being published for gene switch, reflect the growing research efforts of various industry and academic stakeholders. Majority of the authors are affiliated to organizations based in North America. 30 publishers are involved in publishing scientific articles focused on gene switch. MDPI emerged as the most popular publisher, based on number of publications.

More than 360 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field since 2014

The increasing interest of various industry as well as non-industry stakeholders in the gene switch has led to the expansion of intellectual capital in this domain. A number of patents have been filed by companies / organizations in order to protect novel intellectual property generated within this field. It is worth highlighting that majority (91%) of these patents are applications (not having received approval yet), followed by granted patents (8%).

Additionally, majority of the patent assignees are industry players; however, the contribution of non-industry players in the overall patent filing activity has increased considerably during the period 2017-2022. In fact, in 2022, industry and non-industry players have filed 58 and 23 patents, respectively, in the domain of gene switch.

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/gene-switch-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

+1 (415) 800 3415

[email protected]